000 | 01842 a2200517 4500 | ||
---|---|---|---|
005 | 20250516230112.0 | ||
264 | 0 | _c20151102 | |
008 | 201511s 0 0 eng d | ||
022 | _a1948-7193 | ||
024 | 7 |
_a10.1021/cn500119g _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aWang, Zhiren | |
245 | 0 | 0 |
_aDesign, synthesis, and evaluation of multitarget-directed selenium-containing clioquinol derivatives for the treatment of Alzheimer's disease. _h[electronic resource] |
260 |
_bACS chemical neuroscience _cOct 2014 |
||
300 |
_a952-62 p. _bdigital |
||
500 | _aPublication Type: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 |
_aAlzheimer Disease _xdrug therapy |
650 | 0 | 4 |
_aAmyloid beta-Peptides _xmetabolism |
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aAntioxidants _xchemical synthesis |
650 | 0 | 4 |
_aBlood-Brain Barrier _xmetabolism |
650 | 0 | 4 | _aCapillary Permeability |
650 | 0 | 4 | _aCell Line, Tumor |
650 | 0 | 4 |
_aCell Survival _xdrug effects |
650 | 0 | 4 |
_aClioquinol _xanalogs & derivatives |
650 | 0 | 4 |
_aCopper _xtoxicity |
650 | 0 | 4 | _aDrug Design |
650 | 0 | 4 | _aDrug Evaluation, Preclinical |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aHydrogen Peroxide _xmetabolism |
650 | 0 | 4 | _aMembranes, Artificial |
650 | 0 | 4 | _aModels, Biological |
650 | 0 | 4 |
_aNootropic Agents _xchemical synthesis |
650 | 0 | 4 |
_aPeptide Fragments _xmetabolism |
650 | 0 | 4 |
_aProtein Multimerization _xdrug effects |
650 | 0 | 4 |
_aSelenium Compounds _xchemical synthesis |
650 | 0 | 4 | _aSwine |
700 | 1 | _aWang, Yali | |
700 | 1 | _aLi, Wenrui | |
700 | 1 | _aMao, Fei | |
700 | 1 | _aSun, Yang | |
700 | 1 | _aHuang, Ling | |
700 | 1 | _aLi, Xingshu | |
773 | 0 |
_tACS chemical neuroscience _gvol. 5 _gno. 10 _gp. 952-62 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1021/cn500119g _zAvailable from publisher's website |
999 |
_c24096327 _d24096327 |